AmacaThera and Pacira BioSciences Sign $230 Million Licensing Deal for Long-Acting Anesthetic

Nov 4, 2025
AmacaThera has entered into an exclusive global licensing agreement with Pacira BioSciences worth up to $230 million to develop AMT-143, a long-acting non-opioid anesthetic for post-operative pain. Pacira will fund clinical development, manufacturing, and commercialization, with Phase 2 trials expected to start in 2026.

In a press release, AmacaThera announced an exclusive global licensing agreement with Pacira BioSciences valued at up to $230 million for AMT-143, AmacaThera’s long-acting non-opioid anesthetic designed for post-operative pain management.

AmacaThera will receive $5 million upfront and up to $225 million in potential milestone payments. AMT-143 leverages AmacaThera’s tunable hydrogel platform, which enables sustained local release of ropivacaine to provide extended pain relief.

Under the agreement, Pacira will fund the clinical development, manufacturing, and commercialization of AMT-143. Both companies plan to initiate a Phase 2 clinical trial in 2026, with AmacaThera leading select studies before Pacira assumes full responsibility for later-stage development and commercialization.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.